Idiopathic pulmonary fibrosis (IPF) remains an area of high unmet clinical need. GlobalData has identified four key unmet needs in this disease space, including increased earlier diagnosis, improved drug safety and efficacy, improvement in patient quality of life, and treatments for patients with severe disease.

Key opinion leaders interviewed by GlobalData noted that it is challenging to definitively diagnose IPF early in the clinical course of the disease. Read more here.